ALPS Medical Breakthroughs ETF (SBIO)
Upgrades & Downgrades
Latest SBIO news
SBIO Outpaced XBI, IBB in Volatile Last Week
21 September 2022
Despite last week's volatility, positive sentiment throughout the biotech industry continued to intensify, propelled by favorable legislation and encouraging trial data.
SBIO Was ALPS' Top Performing ETF in August
1 September 2022
The ALPS Medical Breakthroughs ETF (SBIO) was ALPS' top-performing ETF in August, propelled by positive earnings and M&A announcements in the portfolio. SBIO increased 8.65% on a total return basis ...
Biotech ETFs Slip After Novavax Cuts 2022 Guidance
11 August 2022
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Gen...
Biotech & Crypto -- Best ETF Areas of Last Week
8 August 2022
Biotech and cryptocurrency -- two ETF areas outperformed last week.
Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal
5 August 2022
Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Vir...
Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics
4 August 2022
Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday...
SBIO Increases on Biotech's Sustained Rebound
20 July 2022
A surge in biotech stocks that began in mid-June is lasting longer than skeptics expected, with no signs of slowing down. The ALPS Medical Breakthroughs ETF (SBIO) gained 7.74% in June as positive dru...
5 ETFs Riding High on the Biotech Comeback
8 July 2022
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Biotech ETFs Are Making a Comeback
5 July 2022
Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech ...